HK Stock Movement | CANSINOBIO (06185) Rises Over 4% Again, Q3 Net Profit Surges 8-Fold YoY with Core Product MenHibrix Showing Strong Growth

Stock News

Oct 31

CANSINOBIO (06185) rose over 4% again, trading at HK$45.98 by press time, up 3.84%, with a turnover of HK$25.51 million. The company reported strong Q3 results, with revenue reaching RMB310 million, up 17.67% YoY, and net profit attributable to shareholders surging 842.01% YoY to RMB27.93 million. For the first three quarters, revenue totaled RMB693 million, a 22.13% YoY increase, while net profit swung to a profit of RMB14.44 million from a loss in the same period last year.

The robust performance was driven by strong market uptake of its core product, MenHibrix, the only quadrivalent meningococcal conjugate vaccine in China's meningitis vaccine market. Its innovative advantages have boosted market share, contributing to the 22.13% revenue growth in the first nine months.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/1168252835"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1168252835\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1168252835?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-31 11:20","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1168252835","market":"fut","top_or_hot":-1,"title":"HK Stock Movement | CANSINOBIO (06185) Rises Over 4% Again, Q3 Net Profit Surges 8-Fold YoY with Core Product MenHibrix Showing Strong Growth","media":"Stock News","content":"<p>CANSINOBIO (06185) rose over 4% again, trading at HK$45.98 by press time, up 3.84%, with a turnover of HK$25.51 million. The company reported strong Q3 results, with revenue reaching RMB310 million, up 17.67% YoY, and net profit attributable to shareholders surging 842.01% YoY to RMB27.93 million. For the first three quarters, revenue totaled RMB693 million, a 22.13% YoY increase, while net profit swung to a profit of RMB14.44 million from a loss in the same period last year.</p>\n<p>The robust performance was driven by strong market uptake of its core product, MenHibrix, the only quadrivalent meningococcal conjugate vaccine in China's meningitis vaccine market. Its innovative advantages have boosted market share, contributing to the 22.13% revenue growth in the first nine months.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>HK Stock Movement | CANSINOBIO (06185) Rises Over 4% Again, Q3 Net Profit Surges 8-Fold YoY with Core Product MenHibrix Showing Strong Growth</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHK Stock Movement | CANSINOBIO (06185) Rises Over 4% Again, Q3 Net Profit Surges 8-Fold YoY with Core Product MenHibrix Showing Strong Growth\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-10-31 11:20</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>CANSINOBIO (06185) rose over 4% again, trading at HK$45.98 by press time, up 3.84%, with a turnover of HK$25.51 million. The company reported strong Q3 results, with revenue reaching RMB310 million, up 17.67% YoY, and net profit attributable to shareholders surging 842.01% YoY to RMB27.93 million. For the first three quarters, revenue totaled RMB693 million, a 22.13% YoY increase, while net profit swung to a profit of RMB14.44 million from a loss in the same period last year.</p>\n<p>The robust performance was driven by strong market uptake of its core product, MenHibrix, the only quadrivalent meningococcal conjugate vaccine in China's meningitis vaccine market. Its innovative advantages have boosted market share, contributing to the 22.13% revenue growth in the first nine months.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1191","symbol_name":"制药","start_time":0,"source_url":"","article_id":"1168252835","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1168252835","pubTimestamp":1761880838,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"CANSINOBIO (06185) rose over 4% again, trading at HK$45.98 by press time, up 3.84%, with a turnover of HK$25.51 million. The company reported strong Q3 results, with revenue reaching RMB310 million,...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1191":"制药","BK1515":"抗疫概念","BK1161":"生物科技","BK1574":"生物医药B类股","06185":"康希诺生物"},"translate_title":"港股动向|康希诺生物(06185)再涨超4%Q3净利同比暴增8倍核心产品MenHibrix增长强劲","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"06185":1},"content_text":"CANSINOBIO (06185) rose over 4% again, trading at HK$45.98 by press time, up 3.84%, with a turnover of HK$25.51 million. The company reported strong Q3 results, with revenue reaching RMB310 million, up 17.67% YoY, and net profit attributable to shareholders surging 842.01% YoY to RMB27.93 million. For the first three quarters, revenue totaled RMB693 million, a 22.13% YoY increase, while net profit swung to a profit of RMB14.44 million from a loss in the same period last year.\nThe robust performance was driven by strong market uptake of its core product, MenHibrix, the only quadrivalent meningococcal conjugate vaccine in China's meningitis vaccine market. Its innovative advantages have boosted market share, contributing to the 22.13% revenue growth in the first nine months.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}